Capricor Therapeutics CAPR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.42M+266% | $287.85M+2,450% | $19.51M-71.5% | $23.24M+117% | $28.79M+363% | ||
| $173.19M+49.3% | $30.28M-78.4% | $79.06M+375% | $99.56M+430% | $115.98M+244% | ||
| $283.09M+93.6% | $322.94M+97.7% | $100.95M+17.6% | $124.13M+305% | $146.25M+253% | ||
| $28.5M+365% | $18.31M+229% | $11.07M+108% | $8M+42.3% | $6.13M+4.1% | ||
| $326.28M+112% | $355.95M+109% | $126.44M+36.0% | $133.57M+249% | $153.77M+211% | ||
| $3.93M-25.2% | $1.65M-49.6% | $2.72M-58.4% | $4.81M-22.0% | $5.25M-15.9% | ||
| $12M0.0% | $12M0.0% | $12M-8.6% | $12M-22.0% | $12M-38.0% | ||
| $33.64M+50.6% | $35.84M+70.4% | $28.15M+37.5% | $28.4M+27.0% | $22.34M-15.3% | ||
| $13.94M+269% | $14.32M+259% | $14.42M+242% | $194.6K-95.6% | $3.78M-18.2% | ||
| $47.58M+82.2% | $50.16M+100% | $42.57M+72.4% | $28.59M+6.8% | $26.12M-15.8% | ||
| $57.67K+26.2% | $57.37K+25.9% | $45.72K+13.4% | $45.71K+42.9% | $45.68K+44.5% | ||
| -$338.82M-51.1% | -$304.88M-52.6% | -$274.71M-42.5% | -$250.14M-38.8% | -$224.23M-32.6% | ||
| $278.7M+118% | $305.79M+110% | $83.87M+22.9% | $104.98M+813% | $127.65M+592% | ||
| $326.28M+112% | $355.95M+109% | $126.44M+36.0% | $133.57M+249% | $153.77M+211% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Capricor Therapeutics cover its short-term obligations?
- Its current ratio is 8.42 — current assets exceed current liabilities.
- Where does Capricor Therapeutics's balance sheet data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.